Paula Muniz

Senior Director Model Informed Development
CTI Clinical Trial and Consulting Services, Spain
Paula Muniz Piniella is a Senior Director at Model Informed Development group. She is a doctor in Pharmacy by the U of Navarra with a PhD in cardiovascular pharmacology. She is also a MSc in Clinical Research by the U of Cardiff and MBA by the Barcelona School of Managment from de U Pompeu Fabra. Paula has more than 20 years of experience within pharmaceutical industry in an international setting where she has worked on regulatory strategy, clinical study design and result evaluation in several indications for a NCE and a fixed dose combination for EMA and FDA submissions. Focusing on comparative bioavailability, in vivo in vitro relationships/correlations and pragmatic application of regulatory requirements, she has participated in the development of numerous complex immediate and modified release pharmaceutical alternatives for oral, inhalation and intramuscular routes.

Events/Masterclasses Paula Muniz is currently speaking at

Pharma

Advanced IVIVC Professional
Online Live Stream
Join Advanced IVIVC Professional training to understand the selection of the most appropriate data to establish IVIVC.

Are you interested in a custom-made event with this trainer?

Contact us to Request more information about your custom-made Corporate Learning program.

REQUEST MORE INFORMATION

Paula Muniz
Senior Director Model Informed Development
CTI Clinical Trial and Consulting Services, Spain
Paula Muniz Piniella is a Senior Director at Model Informed Development group. She is a doctor in Pharmacy by the U of Navarra with a PhD in cardiovascular pharmacology. She is also a MSc in Clinical Research by the U of Cardiff and MBA by the Barcelona School of Managment from de U Pompeu Fabra. Paula has more than 20 years of experience within pharmaceutical industry in an international setting where she has worked on regulatory strategy, clinical study design and result evaluation in several indications for a NCE and a fixed dose combination for EMA and FDA submissions. Focusing on comparative bioavailability, in vivo in vitro relationships/correlations and pragmatic application of regulatory requirements, she has participated in the development of numerous complex immediate and modified release pharmaceutical alternatives for oral, inhalation and intramuscular routes.
Paula Muniz
Description